DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Hyatt Regency Bethesda

2015 年 04 月 13 日 7:00 上午 - 2015 年 04 月 15 日 12:00 下午

One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814-5326

CMC Workshop 2015

Session 8A: Modelling (Chemicals)

Session Chair(s)

Frank  Montgomery, PHD

Frank Montgomery, PHD

Global Head Regulatory CMC, GRAPSQA

AstraZeneca, United Kingdom

The Points to Consider ICH Endorsed Guide for ICH Q8/Q9/Q10 Implementation describes the use of models and their categorization from high to low impact depending on level of risk to patient when used as part of the control strategy. There are a variety of ways that this information can be incorporated into the control strategy to assure product quality and process consistency as part of a marketing application. This session will look at a variety of ways that models have been used to support marketing applications, the data and statistical analysis that was needed gain approval, and some considerations of how this could evolve in the future. For example a Design Space may be associated with RTRT, or may be part of a control strategy that includes extensive end-product testing; consequently the degree of assurance and the level of statistical confidence required can vary.

Speaker(s)

John  Lepore, PHD

Model Implementation: It Really Is All About the Control Strategy

John Lepore, PHD

Merck & Co. Inc., United States

QbD and CMC Practices Lead, Global Pharmaceutical Commercialization

Matt  Popkin, PHD

Science and Strategy: The Role of Models in Achieving Manufacturing Flexibility

Matt Popkin, PHD

GSK, United Kingdom

Senior Director, CMC Excellence, Global Regulatory Affairs

Nathan  Ide

Statistical Models and Tools for the Assessment of Process Parameter Criticality

Nathan Ide

Pfizer, United States

Senior Principal Scientist

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。